Navigation Links
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning

EAST NORRITON, Pa., July 23 /PRNewswire/ -- Tengion Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, today announced that it has appointed Mark Stejbach as Vice President, Marketing and Commercial Planning. Mr. Stejbach brings more than twenty years of marketing, sales, finance, and managed care experience from both Merck & Co., Inc. and Biogen, Inc.

"We are very pleased to welcome Mark to the Tengion executive team as we are advancing our Neo-Bladder clinical trial programs along with commercial planning activities," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "Mark brings extensive experience and a proven track record in both large pharma and biotech, including the successful launch of AVONEX for multiple sclerosis. His broad expertise in managing commercial activities across all stages of product development, and in specialty markets, will provide key insights to Tengion as we continue to grow and move our clinical pipeline toward commercialization in the US and Europe."

Mr. Stejbach started his pharma career at Merck in 1987 and went on to lead marketing campaigns for VASOTEC and PROSCAR. From 1994 to 1997, Mr. Stejbach worked for Biogen, Inc. developing and executing the launch marketing plan for the company's highly successful first marketed product, AVONEX, for multiple sclerosis. He then rejoined Merck in 1997 and since that time has held numerous senior leadership positions within the company including Senior Director roles in market development, specialty sales, marketing, and investor relations; and Vice President, Sales Services prior to his most recent role of Vice President of Managed Care Marketing in Merck's United States Pharmaceutical division. Mr. Stejbach earned his MBA from The Wharton School, University of Pennsylvania, and a BS in mathematics from Virginia Tech. He was recently named a 2008 Emerging Pharma Leader by Pharmaceutical Executive magazine.

"I am thrilled to join Tengion at what is an extremely exciting time for the company," commented Mr. Stejbach. "As Tengion continues to advance its Neo-Bladder Augment, Conduit and Replacement programs, I look forward to helping the Company achieve its ultimate goal of successfully bringing unique and compelling medical advances to patients in need."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.

SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
2. Tengion Appoints Jeff Randall to Board of Directors
3. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
5. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
6. AMT Appoints Director Global Marketing and Sales
7. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
9. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
10. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
11. Transcept Pharmaceuticals Appoints Key Senior Executives
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, ... and rodent control solutions , Bird Free, ... works across all sensory modalities including visual, smell, taste and touch, enabling safe, effective ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... la première fois les différences entre les souches ... de celles des êtres humains . Ces ... comprendre et envisager la prise en charge efficace de ... ent diagnostiqués chez les chats .    --> ...
Breaking Biology Technology:
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):